Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Get 50% off discount for CGT related product lines!
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one! Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers ! Time Limited Offer: Welcome Gift for New Customers !
5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1 μg/mL of AF488-Labeled Human BCMA, His Tag (Cat. No. BCA-HA2H8) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF488 signal was used to evaluate the binding activity (QC tested).
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Janssen Global Services Llc | TECAYLI | EU | Multiple Myeloma | Janssen Biotech Inc | 2022-08-23 | Hematologic Diseases; Hematologic Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
| Ciltacabtagene autoleucel | JNJ-4528; LCAR-B38M; JNJ-68284528 | Approved | Nanjing Legend Biotechnology Co Ltd | Carvykti | United States | Multiple Myeloma | Nanjing Legend Biotechnology Co Ltd, Janssen Research & Development Llc | 2022-02-28 | Multiple Myeloma | Details |
| Idecabtagene vicleucel | bb-2121 | Approved | Bluebird Bio Inc | Abecma | United States | Multiple Myeloma | Celgene Corp | 2021-03-26 | Multiple Myeloma | Details |
| Belantamab mafodotin | GSK-2857916; GSK2857916 | Approved | Glaxosmithkline Plc | BLENREP | EU | Multiple Myeloma | Glaxosmithkline (Ireland) Ltd | 2020-08-05 | Bone Marrow Neoplasms; Lymphoma, B-Cell; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Amyloidosis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| IBI-346 | IBI-346 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| CAR-BCMA(Sheba Medical Center) | Phase 2 Clinical | Sheba Medical Center, Israel | Multiple Myeloma | Details | |
| C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
| Anti-BCMA CAR-NK Cell Therapy (Sichuan Kelun-Biotech) | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Multiple Myeloma | Details | |
| AMG-224 | AMG-224 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| ACLX-001 | ACLX-001 | Phase 1 Clinical | Arcellx Inc | Multiple Myeloma | Details |
| Anti-BCMA/CD19 CAR-T Therapy(University College London) | Phase 1 Clinical | University College London | Multiple Myeloma | Details | |
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic | Details | |
| WVT-078(Novartis Pharma) | WVT-078 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| LCAR-B4822M | LCAR-B4822M | Phase 1 Clinical | Genscript Biotech Corp | Multiple Myeloma | Details |
| Azintuxizumab | TNB-383B; ABBV-383 | Phase 2 Clinical | Teneobio Inc, Abbvie Inc | Multiple Myeloma | Details |
| EMB-06 | EMB-06; EMB06 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma | Details |
| Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) | LCAR-BCX | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) | Descartes-08 | Phase 2 Clinical | Cartesian Therapeutics Inc | Myasthenia Gravis; Multiple Myeloma | Details |
| CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| Humanized CART Directed Against BCMA | ARI-0002h | Phase 2 Clinical | Instituto De Salud Carlos Iii | Multiple Myeloma | Details |
| Descartes-11 | Descartes-11; Descartes-011 | Phase 2 Clinical | Cartesian Therapeutics Inc | Multiple Myeloma | Details |
| HDP-101 | HDP-101; HDP101-ATAC | Phase 2 Clinical | Heidelberg | Paraproteinemias; Multiple Myeloma | Details |
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase 3 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia; Multiple Myeloma | Details | |
| AUTO-2 | AUTO-2; SUB-96123 | Phase 1 Clinical | Autolus | Multiple Myeloma | Details |
| Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Chongqing Xinqiao Hospital | Multiple Myeloma | Details | |
| Motacabtagene lurevgedleucel | CTX-120 | Phase 1 Clinical | Crispr Therapeutics Ag | Multiple Myeloma | Details |
| GR-1803 | GR-1803 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Multiple Myeloma | Details |
| MCARH-125 | MCARH-125 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) | Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details | |
| BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 1 Clinical | The First Affiliated Hospital Of Nanchang University | Multiple Myeloma | Details | |
| Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) | Phase 1 Clinical | Persongen Biotherapeutics | Multiple Myeloma | Details | |
| SEA-BCMA | SEA-BCMA; SGN-BCMA | Phase 1 Clinical | Seattle Genetics Inc | Multiple Myeloma | Details |
| PBCAR-269A | PBCAR-269A | Phase 2 Clinical | Precision Biosciences Inc | Multiple Myeloma | Details |
| BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Multiple Myeloma | Details | |
| FT-576 | FT-576 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
| Alnuctamab | CC-93269; EM-901 | Phase 1 Clinical | Multiple Myeloma | Details | |
| C-CAR088 | C-CAR088 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University, OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
| JWCAR129 | JWCAR129; JWCAR-129 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | POEMS Syndrome | Details | |
| HY-027 | HY-027 | Phase 1 Clinical | Multiple Myeloma | Details | |
| F-182112 | F-182112; F182112 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| Ispectamab debotansine | CC-99712; BMS-986352; SP-8919 | Phase 1 Clinical | Multiple Myeloma | Details | |
| MEDI-2228 | MEDI-2228 | Phase 1 Clinical | Medimmune Llc | Multiple Myeloma | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details | |
| REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| CM-336(Connaught Biomedical Technology) | CM-336 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| CC-98633 | CC-98633 | Phase 1 Clinical | Multiple Myeloma | Details | |
| Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Neoplasms | Details | |
| BCMA-NKE | BCMA-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| ACTR 087/SEA BCMA combination therapy | Phase 1 Clinical | Unum Therapeutics Inc | Multiple Myeloma | Details | |
| BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma | Details | |
| BCMA-UCART cell therapy (Shanghai Bioray Laboratory) | Clinical | Bioray Laboraytories Inc | Multiple Myeloma | Details | |
| BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell | Details | |
| BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) | Phase 2 Clinical | Asclepius Technology Company Group | Multiple Myeloma | Details | |
| Orvacabtagene autoleucel | ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 | Phase 2 Clinical | Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc | Multiple Myeloma | Details |
| CART-BCMA | MTV-273; CART-BCMA | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma | Details |
| Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
| CART-BCMA(Simnova) | SNC-102(Simnova); SNC102(Simnova) | Phase 2 Clinical | Shanghai Simnova Biotechnology Co Ltd | Multiple Myeloma | Details |
| GC-012F | GC-012F | Phase 2 Clinical | Multiple Myeloma; Lymphoma, Non-Hodgkin | Details | |
| BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) | CBG-002 CAR-T | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Neoplasms; Multiple Myeloma | Details |
| Elranatamab | PF-06863135 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| NXC-201 | HBI-0101; NXC-201 | Phase 1 Clinical | Hadassah Medical Organization, Immix Biopharma | Multiple Myeloma | Details |
| ALLO-605 | ALLO-605; ALLO605 | Phase 2 Clinical | Allogene Therapeutics Inc | Multiple Myeloma | Details |
| Linvoseltamab | REGN-5458 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| ALLO-715 | ALLO-715 | Phase 1 Clinical | Allogene Therapeutics Inc, Cellectis Sa | Multiple Myeloma | Details |
| Pacanalotamab | AMG-420; BI-836909 | Phase 1 Clinical | Micromet Inc | Multiple Myeloma | Details |
| bb-21217 | bb-21217 | Phase 1 Clinical | Bluebird Bio Inc, Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| Anti-BCMA CAR T-cell therapy (Arcellx) | CART-ddBCMA | Phase 2 Clinical | Arcellx Inc | Multiple Myeloma | Details |
| BCMA TriTAC | HPN-217 | Phase 1 Clinical | Harpoon Therapeutics, Abbvie Inc | Multiple Myeloma | Details |
| Belantamab | GSK2857914; GSK-2857914 | Phase 2 Clinical | Glaxosmithkline Plc | Multiple Myeloma | Details |
| CB-011 | CB-011 | Phase 1 Clinical | Caribou Biosciences Inc | Multiple Myeloma | Details |
| BCMA CAR-T Cells (Pregene) | PRG-1801 | Phase 2 Clinical | Multiple Myeloma | Details | |
| PHE-885 | PHE-885 | Phase 2 Clinical | Novartis Pharma Ag | Hematologic Neoplasms; Multiple Myeloma | Details |
This web search service is supported by Google Inc.
A-Z
